Candriam S.C.A. V Tv Therapeutics Inc. Transaction History

Candriam S.C.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 09, 2018	SELL	$3.91 - $7.83 $351,900 - $704,700	-90,000 Closed	0 $0
Q4 2017 Feb 07, 2018	SELL	$3.9 - $7.77 $195,000 - $388,500	-50,000 Reduced 35.71%	90,000 $541,000
Q3 2017 Nov 03, 2017	BUY	$3.83 - $6.07 $536,200 - $849,800	140,000	140,000 $837,000

243K

Ticker VTVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,483,600
Market Cap $1.2B
Description
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetran...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.